The Acalabrutinib Market is witnessing substantial growth, driven by increasing demand for targeted therapies in the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). This next-generation Bruton tyrosine kinase (BTK) inhibitor is reshaping oncology landscapes due to its precision and improved safety profile.